DA1, a peptide that competitively binds to DRP1, can selectively disrupt ATAD3A–DRP1 interaction and eventually suppress mitochondrial fragmentation and mtDNA lesion; notably, this peptide has been used in Huntington’s disease mouse- and patient-derived cells to reduce bioenergetic deficits and cell death [12]. The gene discussed is DNM1L; the disease is juvenile Huntington disease.